Induced pluripotent stem cells: A new strategy to model human cancer. (February 2019)

• Record Type: Journal Article
• Authors: Bindhya, S.; Sidhanth, C.; Shabna, A.; Krishnapriya, S.; Garg, M.; Ganesan, T.S.
• Is Part Of: International journal of biochemistry & cell biology. Volume 107(2019)
• Page Start: 62
• Page End: 68
• Publication Date: 2019-02
• Subjects: iPSCs Induced Pluripotent Stem Cells -- OCT4 Octamer -Binding Transcription Factor 4 -- SOX2 Sex Determining Region Y -- KLF4 Krupple -Like Factor 4 -- SSEA Stage-Specific Embryonic Antigen -- TRA-1 Tumour Rejection Antigen 1 -- MEF Mouse Embryonic Fibroblast -- hTERT Human Telomerase Reverse Transcriptase -- NOD Non-Obese Diabetic -- SCID Severe Combined Immunodeficiency -- SV40 Simian Virus 40 -- CSC Cancer Stem Cells; iPSCs -- Stem cells -- Pathogenesis -- Cancer -- In vitromodels; Biochemistry -- Periodicals; Cytology -- Periodicals; Biochemistry -- Periodicals; Cell Biology -- Periodicals; Biochimie -- Périodiques; Cytologie -- Périodiques; Biochimie; Cytologie; Biochemistry; Cytology; Ressource Internet (Descripteur de forme); Périodique électronique (Descripteur de forme); Periodicals; 572.05
• DOI: 10.1016/j.biocel.2018.12.008
• Languages: English
• ISSNs: 1357-2725

Abstract

Abstract: Induced pluripotent stem cells are derived from adult somatic cells by ectopic expression of stem cell factors OCT4, SOX2, MYC and KLF4. These cells have characteristic features similar to embryonic stem cells. Although there exists in vitro and in vivo models of cancer, recapitulating the earliest events in the pathogenesis remain challenging. More recently, induced pluripotent stem cells have been generated to model human disease and cancer. There are advantages in the cancer models derived from these cells as compared to existing conventional approaches. Induced pluripotent stem cells have been generated from cancer cell lines, primary tumours and from those with an inherited predisposition to develop cancer. In addition, these cells provide a valuable tool in understanding the pathogenesis of familial cancer in its earliest stages, and to identify additional genetic alterations that are required to develop cancer. Furthermore, these cells can serve as a resource in drug screening and developing new therapies.